ArticleGastroenterology report2026
Intestinal autotransplantation for complex intra-abdominal diseases previously considered unresectable: a systematic review and single-arm meta-analysis.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intestinal autotransplantation (IATx) facilitates radical resection for advanced intra-abdominal cancers involving major vessels, which were previously deemed unresectable. This study systematically reviewed and meta-analyzed its perioperative safety and mid-term survival outcomes. Methods: A search of databases was conducted up to December 2025, adhering to PRISMA guidelines. Studies reporting outcomes of IATx were included in the review. A total of 12 studies involving 160 patients were reviewed, with meta-analysis performed on six studies comprising 122 patients, using random-effects models. Primary outcomes included the 3-year overall survival (OS) rate, 90-day mortality, major complications (Clavien-Dindo ≥ III), and R0 resection rates. Secondary outcomes involved cold ischemia time, operative time, and length of hospital stay. Study quality was assessed by using the MINORS criteria. Results: The pooled 3-year OS rate was 57.9% (95% CI, 34.1%-75.7%; 4 studies; Conclusions: IATx for unresectable complex intra-abdominal tumors demonstrates high R0 resection rates, low mortality, and encouraging 3-year OS outcomes. Given the procedural complexity, IATx should be performed exclusively at expert centers. Further long-term follow-up studies are necessary to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.